Encodes An Animal Polypeptide Patents (Class 536/23.5)
  • Patent number: 9713626
    Abstract: Pharmaceutical compositions comprising an mRNA-loaded nanoparticle, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3, and wherein the mRNA encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein comprising the amino acid sequence of SEQ ID NO:1 are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: July 25, 2017
    Assignees: RaNA Therapeutics, Inc., Ethris GmbH
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • Patent number: 9694058
    Abstract: The tumor-necrosis factor superfamily member LIGHT (p30; TNFSF-14) is a cytokine for inducing immune responses against tumors. A novel biochemical approach is used to decorate the surface of tumor cells with LIGHT. LIGHT decorated cells can be used to vaccinate and induce effective, sustained immunity against cells expressing neo or pathogen associated antigens. Variants of LIGHT are described that enhance binding to cellular receptors (e.g., LT beta receptor) and decrease regulation by inhibitors (e.g., Decoy Receptor 3) increasing ability to stimulate immunity.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: July 4, 2017
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Carl F Ware, Timothy C. Cheung, Theresia A. Banks
  • Patent number: 9637539
    Abstract: This invention features antibodies that specifically bind to a human Dragon family protein.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: May 2, 2017
    Assignee: The General Hospital Corporation
    Inventors: Clifford J. Woolf, Tarek A. Samad
  • Patent number: 9605042
    Abstract: Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: March 28, 2017
    Assignee: Regents of the University of Minnesota
    Inventors: Karen Hsiao Ashe, Xiaohui Zhao, Michael Anthony Walters, Derek John Hook, Morgan Clotaire Paul Le Naour
  • Patent number: 9598480
    Abstract: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: March 21, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kang Ting, Chia Soo
  • Patent number: 9598484
    Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 21, 2017
    Assignees: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber, Jan Grimm, Fabio Montrasio
  • Patent number: 9549971
    Abstract: The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 24, 2017
    Assignee: GENENTECH, INC.
    Inventors: Weilan Ye, Han Lu
  • Patent number: 9518085
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 13, 2016
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
  • Patent number: 9499847
    Abstract: A primer for the amplification of a DNA template comprising a protelomerase target sequence, particularly for production of closed linear DNA, which primer is capable of specifically binding to a palindromic sequence within a protelomerase target sequence and priming amplification in both directions.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: November 22, 2016
    Assignee: Touchlight IP Limited
    Inventors: Neil Porter, Lisa Caproni, Karen Oliver, Kinga Karbowniczek, Angus Knight
  • Patent number: 9498529
    Abstract: The present invention provides methods for treating or preventing influenza virus infection. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising a type II transmembrane serine protease (TTSP) inhibitor. The TTSP inhibitor preferably functions by inhibiting the proteolytic cleavage of influenza hemagglutinin (HA0) into the functional subunits HA1 and HA2. In certain embodiments, the TTSP inhibitor is an inhibitor of transmembrane protease serine S1 member 2 (TMPRSS2), such as an anti-TMPRSS2 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: November 22, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Lisa A. Purcell Ngambo
  • Patent number: 9447179
    Abstract: This invention concerns affinity tools for oligomeric forms of tau protein. It relates to the field of neurodegeneration, more particularly to the field of tau-related diseases and tauopathy. The invention provides novel tau antibodies and antibody fragments, nucleic acids encoding such antibodies and antibody fragments, cell lines producing such antibodies and antibody fragments, antibody compositions, and kits for the detection of aggregated tau and for the diagnosis of diseases involving aggregated tau. The invention further provides methods for the detection of aggregated tau, for the diagnosis of diseases involving aggregated tau, and for the identification of compositions interfering with the formation and/or stability of tau aggregates.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: September 20, 2016
    Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN, KU RESEARCH & DEVELOPMENT, FUJIREBIO EUROPE N.V.
    Inventors: Joris Winderickx, Eugeen Vanmechelen, Fred Van Leuven
  • Patent number: 9434991
    Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 6, 2016
    Assignee: Juneau Biosciences, LLC.
    Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
  • Patent number: 9403913
    Abstract: Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: August 2, 2016
    Assignee: OvaScience, Inc.
    Inventors: David T. Weaver, Bo Zhang
  • Patent number: 9394359
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 19, 2016
    Assignee: CHINA SYNTHETIC RUBBER CORPORATION
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Patent number: 9388452
    Abstract: The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: July 12, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventor: Peter Matthiessen
  • Patent number: 9321837
    Abstract: The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 26, 2016
    Assignee: UCB PHARMA S.A.
    Inventors: Diane Marshall, Stevan Shaw
  • Patent number: 9290546
    Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: March 22, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Jian Yan
  • Patent number: 9290544
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 22, 2016
    Assignee: The Johns Hopkins University
    Inventors: Marc Alan Ostermeier, Gurkan Guntas
  • Patent number: 9285367
    Abstract: The developed reagent is three-color immunophenotyping reagent for measurement of CD4 positive lymphocytes in peripheral blood. The reagent contains 7-aminoactinomycin D (7-AAD) which intercalates into double stranded DNA and is easily excited at 488 nm. The fluorescence emission of 7-AAD has peak at 670 nm that can be detected with FL3 detector of flow cytometer. The 7-AAD, therefore, stains white blood cells and discriminates it from red blood cells. The reagent also contains fluorescein isothiocyanate (FITC) labeled CD4 monoclonal antibody and phycoerythrin (PE) labeled CD14 monoclonal antibody which are detected with FL1 and FL2 detectors of flow cytometer, respectively. The developed reagent can be used to measure number of CD4 positive lymphocytes in lymphocyte population and monitor monocyte contamination simultaneously. This reagent therefore provides more accuracy results of CD4 positive lymphocyte enumeration.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: March 15, 2016
    Assignees: National Science and Technology Development Agency, The Thailand Research Fund
    Inventor: Watchara Kasinrerk
  • Patent number: 9268862
    Abstract: A tracking system passively tracks and records searches conducted by actual search engine users. The recorded data for each search event preferably includes the search query submitted, the search engine used, the search result item (e.g., web page) selected, the position (e.g., page number) of this item, and the user's IP address. The collected data is aggregated and analyzed to generate data regarding the search queries used to locate and access particular destinations (e.g., web pages and sites). This data may be used for various purposes, such as (1) to generate reports showing, e.g., how users reach a particular destination from different search engines and geographic locations, (2) to select content to display on a destination page, such that the content is relevant to search queries commonly used to locate that page, and (3) to update the database of one search engine to reflect searches conducted on other search engines.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: February 23, 2016
    Assignee: Gere Dev. Applications, LLC
    Inventors: Richard Kazimierz Zwicky, Todd William Hooge, Matthew Dunn
  • Patent number: 9249210
    Abstract: Disclosed is an expression vector system for variants of coagulation Factor VIII (FVIII) and von Willebrand Factor (vWF). In detail, mutant vWF the size of which is significantly reduced by deleting exons but which has remarkably increased FVIII stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with FVIII are disclosed. Use of the mutant vWF with a reduced size enables effective expression of FVIII in a viral vector and significantly enhanced FVIII activity. Further, the viral vector may be effectively used to treat hemophilia through gene therapy.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: February 2, 2016
    Assignee: Korea University Industrial & Academic Collaborative Foundation
    Inventors: Sang Yun Choi, Sang Won Park
  • Patent number: 9228021
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 5, 2016
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Patent number: 9212227
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 15, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Patent number: 9193768
    Abstract: There are provided an angiopoietin-2 (Ang2) derived peptides, polypeptides, and peptide complexes, and a method for inhibition of binding between Ang2 and integrin and prevention and/or treatment of a disease caused by the activation of Ang2 or the binding between Ang2 and integrin using the peptide, polypeptides, and peptide complexes.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: November 24, 2015
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Sang Yeul Han, Chung Ho Kim, Kyung Eun Kim, Hyung-Chan Kim, Kwang-Hoon Lee, Hyo Seon Lee
  • Patent number: 9192650
    Abstract: The present invention provides compositions and methods to prevent apoptosis. In particular, provided herein are compositions and methods which prevent FAS-mediated photoreceptor apoptosis.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 24, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: David N. Zacks, Cagri Besirli
  • Patent number: 9166061
    Abstract: Provided is a transistor which includes an oxide semiconductor film and has stable electrical characteristics. In the transistor, over an oxide film which can release oxygen by being heated, a first oxide semiconductor film which can suppress oxygen release at least from the oxide film is formed. Over the first oxide semiconductor film, a second oxide semiconductor film is formed. With such a structure in which the oxide semiconductor films are stacked, the oxygen release from the oxide film can be suppressed at the time of the formation of the second oxide semiconductor film, and oxygen can be released from the oxide film in later-performed heat treatment. Thus, oxygen can pass through the first oxide semiconductor film to be favorably supplied to the second oxide semiconductor film. Oxygen supplied to the second oxide semiconductor film can suppress the generation of oxygen deficiency, resulting in stable electrical characteristics.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: October 20, 2015
    Assignee: Semiconcductor Energy Laboratory Co., Ltd.
    Inventor: Shunpei Yamazaki
  • Patent number: 9157085
    Abstract: An expression vector for expressing a target polypeptide in a prokaryotic cell is provided. The vector comprises a promoter operably linked to a polynucleotide encoding the target polypeptide operably linked to a eukaryotic secretion leader sequence, the eukaryotic secretion leader sequence encoding a signal peptide sequence selected from the group consisting of: a) MLKRSSWLATLGLLTVASVSTIVYA; b) MKKATFITCLLAVLLVSNPIWNA; c) MKVSAAALAVILIATALCAPASA; d) MKVSTAFLCLLLTVSAFSAQVLA; and e) MKCLLLALGLALACAAQA. Processes for expressing polypeptides and prokaryotic microorganisms comprising such vectors are also provided.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: October 13, 2015
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventors: Bhupendra Vallabh Kara, Christopher David John Lennon
  • Patent number: 9127321
    Abstract: The present invention provides methods and kits that may be used to detect and quantify the presence of Coccidioides species. The methods include quantification PCR assays, and the kits and compositions include oligonucleotides used as primers and probes.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 8, 2015
    Assignees: The Translational Genomics Research Institute, The Arizona Board of Regents on Behalf of Northern Arizona University
    Inventors: David Engelthaler, Elizabeth Driebe, Paul Keim
  • Patent number: 9121853
    Abstract: Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: September 1, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eugene D. Kwon, John Cheville
  • Patent number: 9114116
    Abstract: The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (e.g., hepatocyte secretory factors) for alleviating and/or protecting against neuronal damage (e.g., resulting from stroke), and methods of use thereof.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: August 25, 2015
    Assignee: NORTHWESTERN UNIVERSITY
    Inventor: Shu Q. Liu
  • Patent number: 9101585
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: August 11, 2015
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 9090712
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: July 28, 2015
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Patent number: 9090694
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 28, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Patent number: 9072707
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: July 7, 2015
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventor: Jae Ryoung Hwang
  • Patent number: 9062299
    Abstract: The present invention relates to compositions comprising factor DC coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: June 23, 2015
    Assignee: AMUNIX OPERATING INC.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • Patent number: 9051390
    Abstract: A pharmaceutical formulation and method of treatment of prion disease include a RAP agent with a pharmaceutically acceptable carrier and/or excipient, and the administration of same to a subject suffering from or at risk of a prion disease. The RAP agent is an effective means for the prevention and/or treatment of various prion diseases regardless whether the disease is acquired by infection or by genetic mutation.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: June 9, 2015
    Assignee: American National Red Cross
    Inventors: Larisa Cervenakova, Oksana Yakovleva
  • Patent number: 9045562
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: June 2, 2015
    Assignee: Washington University
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • Patent number: 9045558
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: June 2, 2015
    Assignee: IMMUNEX CORPORATION
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Publication number: 20150148259
    Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 28, 2015
    Inventors: Paul R. Thompson, Kevin L. Bicker, Venkataraman Subramanian
  • Publication number: 20150148293
    Abstract: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 28, 2015
    Inventors: MICHAEL BLABER, JIHUN LEE
  • Publication number: 20150147347
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • Publication number: 20150147349
    Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.
    Type: Application
    Filed: February 15, 2013
    Publication date: May 28, 2015
    Inventors: Timothy A. Springer, Chafen Lu, Gaojie Song, Adem Koksal
  • Publication number: 20150150152
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Publication number: 20150147343
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: July 2, 2014
    Publication date: May 28, 2015
    Applicant: University of Zurich
    Inventors: Roger NITSCH, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Patent number: 9040020
    Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: May 26, 2015
    Assignee: Technische Universitaet Muenchen
    Inventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
  • Patent number: 9040676
    Abstract: The invention concerns a system for modulating tissue physiology, for example, to prevent or reverse tissue damage caused by disease. The system utilizes vigilant cells that include stable vectors containing a gene switch/biosensor and a gene amplification system. The vectors allow expression of a transgene (such as a cardioprotective gene) in the vigilant cells to be regulated in response to a physiological signal, to be switched on or off, and to provide sufficient levels of the transgene product to achieve a desired result, e.g., prevention or reversal of myocardial cell damage. In addition to myocardial infarction, the vectors can be used to treat cells in a number of other disease states, including diabetes, cancer, stroke, and atherosclerosis. These approaches to stem cell-based gene therapy provide a novel strategy not only for treatment but for prevention of cell destruction.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: May 26, 2015
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: M. Ian Phillips, Yao Liang Tang
  • Publication number: 20150141347
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Publication number: 20150141634
    Abstract: Some embodiments provide for a device that collects vesicles and vesicle-like materials from biological fluids. Such devices comprise at least one sample loading region; at least one corresponding vesicle-capture material, wherein said vesicle-capture material comprises glass-like materials; and at least one corresponding sample receiving region, wherein passage of the biological fluid from the sample loading region through the vesicle-capture material and into the sample receiving region results in the capture of vesicles. Additional embodiments provide for a method of isolating vesicles and vesicle-like materials from biological fluids.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 21, 2015
    Inventor: Masato Mitsuhashi
  • Patent number: 9034313
    Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: May 19, 2015
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B Weiner, Jean D Boyer, Michele Kutzler
  • Patent number: 9034598
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein